← back to search

Jan Paul Medema

AbbVie (United States) · US
Area of research
Oncology · Pathology and Forensic Medicine
Research interest
Research interests include Colorectal cancer, Biology, Medicine, Internal medicine, Microsatellite instability, and Wnt signaling pathway.
h-index
citations
7,818
works
24
NIH funding
primary concept
email

Recent publications

The pan-cancer proteome atlas, a mass spectrometry-based landscape for discovering tumor biology, biomarkers, and therapeutic targets
Cancer Cell 2025cited by 34position: middledoi
Enterocyte-like differentiation defines metabolic gene signatures of CMS3 colorectal cancers and provides therapeutic vulnerability
Nature Communications 2025cited by 8position: lastdoi
Data from Practical and Robust Identification of Molecular Subtypes in Colorectal Cancer by Immunohistochemistry
2023cited by 0position: middledoi
Molecular characterization of colorectal cancer related peritoneal metastatic disease
Nature Communications 2022cited by 122position: middledoi
Serum levels of <scp>iCAF</scp>‐derived osteoglycin predict favorable outcome in pancreatic cancer
International Journal of Cancer 2022cited by 14position: middledoi
Serum-based measurements of stromal activation through ADAM12 associate with poor prognosis in colorectal cancer
BMC Cancer 2022cited by 11position: middledoi
Oncogenic BRAF, unrestrained by TGFβ-receptor signalling, drives right-sided colonic tumorigenesis
Nature Communications 2021cited by 79position: middledoi
BCL-XL is crucial for progression through the adenoma-to-carcinoma sequence of colorectal cancer
Cell Death and Differentiation 2021cited by 51position: lastdoi
A RAC-GEF network critical for early intestinal tumourigenesis
Nature Communications 2021cited by 26position: middledoi
Daily practice in guideline adherence to adjuvant chemotherapy in stage III colon cancer and predictors of outcome
European Journal of Surgical Oncology 2021cited by 13position: middledoi
Clinical and biological effects of demethylating agents on solid tumours – A systematic review
Cancer Treatment Reviews 2017cited by 162position: middledoi
Safety, tolerability, and pharmacodynamics of an anti-interleukin-1α/β dual variable domain immunoglobulin in patients with osteoarthritis of the knee: a randomized phase 1 study
Osteoarthritis and Cartilage 2017cited by 69position: lastdoi
Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study
˜The œLancet. Gastroenterology & hepatology 2016cited by 308position: middledoi
Practical and Robust Identification of Molecular Subtypes in Colorectal Cancer by Immunohistochemistry
Clinical Cancer Research 2016cited by 180position: middledoi
The consensus molecular subtypes of colorectal cancer
Nature Medicine 2015cited by 5,209position: middledoi
Phase 1 studies of anti-interleukin-1 dual-variable domain immunoglobulin in healthy subjects and patients with osteoarthritis
Osteoarthritis and Cartilage 2015cited by 3position: lastdoi
Abstract LB-108: Automated immunohistochemistry-based identification of molecular subtypes in colorectal cancer
Cancer Research 2015cited by 0position: middledoi
Essential versus accessory aspects of cell death: recommendations of the NCCD 2015
Cell Death and Differentiation 2014cited by 1,014position: middledoi
Lipid Droplets: A New Player in Colorectal Cancer Stem Cells Unveiled by Spectroscopic Imaging
Stem Cells 2014cited by 256position: middledoi
Reconciliation of classification systems defining molecular subtypes of colorectal cancer
Cell Cycle 2014cited by 75position: lastdoi
Colorectal Cancer Subtyping Consortium (CRCSC) identification of a consensus of molecular subtypes.
Journal of Clinical Oncology 2014cited by 53position: middledoi
Colorectal Cancer Subtyping Consortium (CRCSC) Identifies Consensus of Molecular Subtypes
Annals of Oncology 2014cited by 10position: middledoi
Regulation of stem cell self-renewal and differentiation by Wnt and Notch are conserved throughout the adenoma-carcinoma sequence in the colon
Molecular Cancer 2013cited by 64position: lastdoi
Therapy-resistant tumor microvascular endothelial cells contribute to treatment failure in glioblastoma multiforme
Oncogene 2012cited by 57position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Louis Vermeulen · Cancer Research UK Cambridge Center9 papers (2013–2023)Miriam Koopman · Dutch Colorectal Cancer Group4 papers (2016–2023)Felipe de Sousa e Melo · Amgen (United States)4 papers (2013–2023)Xin Wang · Chinese University of Hong Kong4 papers (2014–2016) · 4 papers (2015–2025)Anne Trinh · University of California, Santa Barbara4 papers (2015–2023)Anguraj Sadanandam · Lawrence Berkeley National Laboratory3 papers (2014–2014)Florian Markowetz · University of Cambridge3 papers (2015–2023)Marnix Jansen · University College London Hospitals NHS Foundation Trust3 papers (2015–2023) · 3 papers (2015–2023)Evelyn Fessler · Ludwig-Maximilians-Universität München3 papers (2015–2023)Sabine Tejpar · University of Lausanne3 papers (2014–2021)G. Johan A. Offerhaus · University Medical Center Utrecht2 papers (2016–2023) · 2 papers (2021–2022)Aurélien de Reyniès · Centre National de la Recherche Scientifique2 papers (2014–2014)René Jackstadt · German Cancer Research Center2 papers (2021–2025)Cornelis J.A. Punt · Oklahoma State University Center for Health Sciences2 papers (2016–2022)Irıs D. Nagtegaal · Nationwide Mutual Insurance Company (United States)2 papers (2016–2023)Krisztián Homicskó · University Hospital of Lausanne2 papers (2014–2014)Edoardo Missiaglia · University Hospital of Lausanne2 papers (2014–2014)